MedTrace Logo

Community-based Primary Care Program Effects on Pharmacotherapy of Type 2 Diabetes and Hypertension in Peru

NCT05979142 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2023-08-07

No results posted yet for this study

Summary

The goal of this observational study is to compare usual care to a community-based primary care program (having components of treatment decisions based on clinical guidelines, self-management education, community health workers, and free health care visits and medications) in low-income Peruvians with type 2 diabetes and/or hypertension.

The main question\[s\] it aims to answer are:

* Compared to pre-program usual care, does the program result in greater benefits, measured as greater proportions of patients with glucose and blood pressure control or maximal quantities and doses of medications?
* Are there greater benefits when the program was provided at home compared to when the program was provided in a clinic?
* Does longer participation in the program result in greater benefits?

Participants will participate in:

* Self-management education provided by community health workers.
* Monitoring of healthy behaviors and glucose, blood pressure, and weight.
* Receipt of free medications for blood pressure, glucose, and heart disease prevention.

Conditions

Interventions

OTHER

community-based primary care program

See group description

Sponsors & Collaborators

  • University of Arizona

    collaborator OTHER

  • Asociación Siempre Salud

    lead OTHER

Principal Investigators

  • John E Deaver, MD · Asociación Siempre Salud

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05979142 on ClinicalTrials.gov